News Search Results
Dec 05, 2025, 09:00 ET The Los Angeles Sports & Entertainment Commission (LASEC) Names Amgen as Official Biotech Partner and Los Angeles World Cup 2026 Host City Supporter Ahead of FIFA World Cup 2026™
change throughout the Los Angeles region.A pioneer of modern biotechnology, Amgen was founded in 1980 in Thousand Oaks, a suburb of Los Angeles. Over the past four decades, the company has grown into a global biotechnology leader, reaching millions of people with its medicines. Its headquarters
More news about: Los Angeles Sports & Entertainment Commission
Dec 05, 2025, 08:33 ET Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC
remains at the forefront of the bioeconomy, safeguarding economic, societal, and national security benefits while maintaining global leadership in biotechnology innovation.
More news about: Ginkgo Bioworks
Dec 05, 2025, 08:00 ET K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appointment of Dr. Shinta Cheng, M.D., Ph.D., as Chief Medical Officer
K36 Therapeutics, Inc. ("K36"), a clinical-stage biotechnology company developing first-in-class MMSET/NSD2 inhibitors for genetically defined cancers, today announced that clinical data from its lead program,
More news about: K36 Therapeutics
Dec 05, 2025, 08:00 ET Jubilant Therapeutics Inc. appoints Daniel J. O'Connor as President and Chief Executive Officer
Dan brings more than 30 years of leadership experience in biotechnology and oncology, with a proven track-record of creating value around differentiated, IP-rich platforms. Most recently, he served as CEO of Ambrx Biopharma,
More news about: Jubilant Therapeutics Inc.
Dec 05, 2025, 07:30 ET Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Dec. 5, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
Dec 04, 2025, 20:00 ET OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies
SHANGHAI, Dec. 4, 2025 /PRNewswire/ -- OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, emerged from stealth and announced today the successful completion
More news about: OTR Therapeutics
Dec 04, 2025, 16:54 ET Human Longevity Expands $1M Cancer Pledge to Redefine Early Detection and Prevention of Colon Cancer
strongest chance to prevent disease or catch it early."About Human LongevityFounded in 2013, Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, AI, and multimodal diagnostics to extend human healthspan. Through its flagship Executive Health
More news about: Human Longevity, Inc.
Dec 04, 2025, 16:05 ET Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Dec. 4, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today the closing of its previously announced private placement
More news about: Virax BioLabs Group Limited
Dec 04, 2025, 13:26 ET Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Dec 04, 2025, 10:34 ET Global Demand for Bio-Fermented Hyaluronic Acid to Triple by 2035 - FMI Forecast
Future Market Insights (FMI) is a leading provider of market intelligence, offering in-depth research across pharmaceuticals, healthcare, biotechnology, and life sciences. With a global research network and advanced analytical frameworks, FMI supports manufacturers, investors, policymakers, and
More news about: Future Market Insights, Inc.
Dec 04, 2025, 10:30 ET Laboratory Software Market worth $10.12 billion by 2030 | MarketsandMarkets™
drive scientific innovation and technological progress. Moreover, increased direct investments from European and North American pharmaceutical and biotechnology companies in Asia are expected to drive the adoption of Laboratory Software solutions in the region.Inquire Before Buying@
More news about: MarketsandMarkets
Dec 04, 2025, 10:01 ET Cleanroom Technologies Market Surges Toward US$10.58 Billion by 2031, Driven by Semiconductor Expansion and Biopharma Sterile Manufacturing
classification system, ISO 3 Cleanrooms are exceptionally clean and provide controlled settings that are appropriate for a variety of industries, including biotechnology, pharmaceuticals, electronics manufacturing, and healthcare. The concentration of particles bigger than 0.5 micrometers in an ISO 3 Cleanroom is
More news about: DataM Intelligence 4 Market Research LLP
Dec 04, 2025, 08:37 ET Korea University Researchers Create Hydrogel Platform for High-Throughput Extracellular Vesicle Isolation
applications in diagnostics, prognosis, and therapeutics."In summary, the meso–macroporous PEGDA hydrogel represents a major advance in EV biotechnology, enabling direct, scalable, and equipment-free EV isolation from diverse biofluids. With high performance and practical versatility, it supports
More news about: Korea University College of Medicine
Dec 04, 2025, 08:00 ET Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3408 for the Treatment of Melanoma
modality for patients."Dr. Meehan recently joined Alpha-9 as Chief Medical Officer, bringing progressive leadership experience in biopharma and biotechnology, specializing in the creation of complex, novel development programs. Dr. Meehan is a board-certified physician trained in hematology and oncology,
More news about: Alpha-9 Oncology, Inc.
Dec 04, 2025, 07:47 ET Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Dec. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates
More news about: Intensity Therapeutics Inc.
Dec 04, 2025, 07:30 ET NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that following a productive discussion with Health Canada
More news about: NeuroSense
Dec 04, 2025, 07:29 ET Amity University Hosts HR Conclave 2025: Strengthening the critical link between Academia and Industry
2026.Amity University Rajasthan, Jaipur, provides students with cutting-edge laboratories for languages, media studies, education, pharmacy, biotechnology, engineering, hotel management, business management, and scientific research, as well as sophisticated facilities for a variety of research projects.The
More news about: Amity University Rajasthan
Dec 04, 2025, 07:00 ET SciNeuro Pharmaceuticals Announces $53 Million Financing to Further Advance Pipeline of Therapies for Neurodegenerative Diseases and Appointment of Chief Financial Officer
Science in Commerce from the University of Virginia.About SciNeuro Pharmaceuticals SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio
More news about: SciNeuro Pharmaceuticals
Dec 04, 2025, 03:00 ET mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar development
The project represents a pioneering step in the application of AI to industrial biotechnology through the creation of a digital twin of the biological process, designed to enhance predictability, consistency, and efficiency in large-scale
More news about: mAbxience
Dec 04, 2025, 03:00 ET mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar development
The project represents a pioneering step in the application of AI to industrial biotechnology through the creation of a digital twin of the biological process, designed to enhance predictability, consistency, and efficiency in large-scale
More news about: mAbxience
Dec 03, 2025, 21:01 ET Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI Officer to Advance A³ Strategy and AI-Driven Drug Discovery
CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced the
More news about: Nona Biosciences
Dec 03, 2025, 19:05 ET Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing
CLICK HERE.Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases.The complaint asserts that, throughout the Class Period, Defendants failed
More news about: Berger Montague
Dec 03, 2025, 19:00 ET High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology
trial via systemic intravenous dosing under the FDA regulatory regime.About ImmViraImmVira is a global leading clinical-stage biotechnology company that is powered by proprietary biological engineering technology, and is dedicated to the discovery, development, manufacture and commercialization
More news about: ImmVira
Dec 03, 2025, 18:10 ET Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Inc.
Dec 03, 2025, 13:53 ET Virax Biolabs Group Limited Announces $5 Million Private Placement
Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today that it has entered into definitive agreements for
More news about: Virax BioLabs Group Limited